Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IRWD 
Ironwood Pharmaceuticals Inc (IRWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IRWD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.95
1 Year Target Price $0.95
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.08% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 173.80M USD | Price to earnings Ratio - | 1Y Target Price 0.95 |
Price to earnings Ratio - | 1Y Target Price 0.95 | ||
Volume (30-day avg) 4 | Beta 0.33 | 52 Weeks Range 0.53 - 5.21 | Updated Date 08/15/2025 |
52 Weeks Range 0.53 - 5.21 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.03 | Actual 0.14 |
Profitability
Profit Margin -2.56% | Operating Margin (TTM) 52.88% |
Management Effectiveness
Return on Assets (TTM) 15.53% | Return on Equity (TTM) -574.72% |
Valuation
Trailing PE - | Forward PE 12.33 | Enterprise Value 679621519 | Price to Sales(TTM) 0.56 |
Enterprise Value 679621519 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA 8.54 | Shares Outstanding 162434000 | Shares Floating 118407983 |
Shares Outstanding 162434000 | Shares Floating 118407983 | ||
Percent Insiders 2.66 | Percent Institutions 96.97 |
Upturn AI SWOT
Ironwood Pharmaceuticals Inc
Company Overview
History and Background
Ironwood Pharmaceuticals, Inc. was founded in 1998. It is a biotechnology company focused on developing and commercializing innovative medicines that address unmet needs in gastrointestinal (GI) diseases. A significant milestone was the approval and launch of Linzess/Constella for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Core Business Areas
- Commercial Products: Includes Linzess/Constella, Ironwood's flagship product for treating IBS-C and CIC. It represents their primary revenue source.
- Research and Development: Focuses on discovering and developing new GI therapies, including those targeting other GI conditions. This includes both early and late stage clinical programs.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, CMO, and other key executives responsible for different business functions. The organizational structure includes departments such as R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Linzess/Constella (linaclotide): A guanylate cyclase-C (GC-C) agonist used for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In the US, Linzess is co-marketed with AbbVie. In Europe it is sold under the name Constella by AbbVie. Linzess/Constella holds a significant market share in the branded IBS-C/CIC market. While specific real-time market share data fluctuates, It competes with generics such as polyethylene glycol 3350, and other branded drugs such as Trulance and Motegrity.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on gastrointestinal disorders is growing, driven by factors such as aging populations, changing diets, and increased awareness of GI conditions. The market includes treatments for IBS, constipation, inflammatory bowel disease (IBD), and other GI ailments.
Positioning
Ironwood is a key player in the branded IBS-C/CIC treatment market, primarily through Linzess/Constella. Their competitive advantage lies in their established brand recognition and clinical efficacy of linaclotide.
Total Addressable Market (TAM)
The total addressable market for IBS and chronic constipation therapies is estimated to be several billion dollars annually. Ironwood is positioned to capture a significant portion of this TAM with Linzess/Constella and future pipeline products.
Upturn SWOT Analysis
Strengths
- Established brand (Linzess/Constella)
- Co-promotion partnership with AbbVie
- Focused expertise in gastrointestinal diseases
- Significant revenue generation
Weaknesses
- Reliance on a single key product (Linzess/Constella)
- Competition from generics and other branded therapies
- Dependence on partner for distribution and marketing
- Risk of clinical trial failures for pipeline products
Opportunities
- Expansion into new markets
- Development of new GI therapies
- Potential acquisitions or partnerships
- Extension of Linzess/Constella's patent life or indications
Threats
- Patent expiration of Linzess/Constella
- Increased competition from generic alternatives
- Regulatory changes impacting drug pricing or approval
- Clinical trial failures or safety concerns
Competitors and Market Share
Key Competitors
- AMGN
- SGYP
- IMMP
Competitive Landscape
Ironwood faces competition from other pharmaceutical companies developing and marketing GI therapies. Its advantages include its established brand and partnership with AbbVie. Disadvantages include reliance on a single key product and competition from generics.
Major Acquisitions
VectivBio Holding AG
- Year: 2023
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Strengthening portfolio with VectivBio's potential blockbuster for Short Bowel Syndrome.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by the success of Linzess/Constella. However, growth rates may fluctuate due to market competition and patent life.
Future Projections: Future growth depends on the continued success of Linzess/Constella, the development and commercialization of new GI therapies, and strategic partnerships or acquisitions. Analyst estimates vary.
Recent Initiatives: Recent strategic initiatives may include pipeline development, market expansion, or cost optimization efforts.
Summary
Ironwood Pharmaceuticals is moderately strong, anchored by the success of Linzess/Constella and its partnership with AbbVie. However, its dependence on a single product and increasing competition present risks. Successful pipeline development and strategic market expansion are crucial for sustained growth. The VectivBio aquisition shows Ironwood Pharmaceuticals Inc. is trying to create a pipeline of blockbuster drugs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Data is not real time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ironwood Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2010-02-03 | CEO & Director Mr. Thomas A. McCourt | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 253 | Website https://ironwoodpharma.com |
Full time employees 253 | Website https://ironwoodpharma.com | ||
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.